Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study | Zendy

Ashish V. Chintakuntlawar | Zendy; Kandelaria M. Rumilla | Zendy; Carin Y. Smith | Zendy; Sarah M. Jenkins | Zendy; Robert L. Foote | Zendy; Jan L. Kasperbauer | Zendy; John C. Morris | Zendy; Mabel Ryder | Zendy; Samer Alsidawi | Zendy; Crystal Hilger | Zendy; Keith C. Bible | Zendy

Open Access

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

Author(s) -

Ashish V. Chintakuntlawar,

Kandelaria M. Rumilla,

Carin Y. Smith,

Sarah M. Jenkins,

Robert L. Foote,

Jan L. Kasperbauer,

John C. Morris,

Mabel Ryder,

Samer Alsidawi,

Crystal Hilger,

Keith C. Bible

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-3756

Subject(s) - medicine , anaplastic thyroid cancer , retrospective cohort study , hazard ratio , immunohistochemistry , oncology , pd l1 , malignancy , cohort , cancer , multimodal therapy , thyroid cancer , confidence interval , pathology , immunotherapy

Anaplastic thyroid cancer (ATC) is rare and a highly fatal malignancy. The role of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) as prognostic and/or predictive markers in ATC is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research